<DOC>
	<DOCNO>NCT01260194</DOCNO>
	<brief_summary>This open-label , multi-center study evaluate efficacy safety Herceptin ( trastuzumab ) combination standard chemotherapy first-line treatment patient HER2 positive metastatic adenocarcinoma stomach gastro-esophageal junction . Patients receive standard chemotherapy maximum 6 cycle , 8 mg/kg Herceptin load dose day 1 , follow 6 mg/kg intravenous infusion every 3 week disease progression .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Combination With Standard Chemotherapy Patients With HER Positive Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Histologically confirm adenocarcinoma stomach gastroesophageal junction advance metastatic disease , amenable curative therapy Measurable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST ) HER2 positive tumor ( primary tumor metastasis ECOG Performance status 0 , 1 2 Life expectancy least 3 month Previous chemotherapy advance metastatic disease less 6 month study start Lack physical integrity upper gastrointestinal tract malabsorption syndrome ( patient partial total gastrectomy allow participate study ) Patients active ( significant uncontrolled ) gastrointestinal bleed Residual relevant toxicity result previous chemotherapy Other malignancy within last 5 year ( except carcinoma situ cervix , basal cell carcinoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>